Skip to main content

Dental Pain

5
Pipeline Programs
7
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Alkermes
AlkermesDUBLIN 4, Ireland
2 programs
1
1
ketorolacPhase 3
N1539Phase 21 trial
Active Trials
NCT00945763Completed230Est. Nov 2009
Lotus Pharmaceuticals
Lotus PharmaceuticalsTaiwan - Taipei
1 program
1
Bupivacaine liposomePhase 31 trial
Active Trials
NCT02517905Completed166Est. Jan 2016
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GW406381Phase 3
Pfizer
PfizerNEW YORK, NY
1 program
1
ARRY-371797, p38 inhibitor; oralPhase 21 trial
Active Trials
NCT00542035Completed103Est. Feb 2008
IBSA Institut Biochimique
IBSA Institut BiochimiqueSwitzerland - Lugano-Pazzallo
2 programs
Diclofenac HPBCDPHASE_31 trial
Diclofenac HPBCD s.c. 75mg/mlPHASE_31 trial
Active Trials
NCT00942448Completed306Est. Apr 2010
NCT00943098Completed142Est. May 2010
Xenon Pharmaceuticals
1 program
XPF-001PHASE_21 trial
Active Trials
NCT00954356Completed61Est. Dec 2009
GSK
GSKLONDON, United Kingdom
1 program
GW406381PHASE_31 trial
Active Trials
NCT00114049Completed300Est. Apr 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lotus PharmaceuticalsBupivacaine liposome
IBSA Institut BiochimiqueDiclofenac HPBCD s.c. 75mg/ml
IBSA Institut BiochimiqueDiclofenac HPBCD
GSKGW406381
Xenon PharmaceuticalsXPF-001
AlkermesN1539
PfizerARRY-371797, p38 inhibitor; oral

Clinical Trials (7)

Total enrollment: 1,308 patients across 7 trials

NCT02517905Lotus PharmaceuticalsBupivacaine liposome

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

Start: Aug 2015Est. completion: Jan 2016166 patients
Phase 3Completed
NCT00943098IBSA Institut BiochimiqueDiclofenac HPBCD s.c. 75mg/ml

Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery

Start: Sep 2009Est. completion: May 2010142 patients
Phase 3Completed
NCT00942448IBSA Institut BiochimiqueDiclofenac HPBCD

Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery

Start: Sep 2009Est. completion: Apr 2010306 patients
Phase 3Completed
NCT00114049GSKGW406381

Dental Pain (Following Third Molar Tooth Extraction) Study

Start: Dec 2004Est. completion: Apr 2005300 patients
Phase 3Completed
NCT00954356Xenon PharmaceuticalsXPF-001

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Start: Sep 2009Est. completion: Dec 200961 patients
Phase 2Completed
NCT00945763AlkermesN1539

Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery

Start: Jul 2009Est. completion: Nov 2009230 patients
Phase 2Completed
NCT00542035PfizerARRY-371797, p38 inhibitor; oral

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

Start: Nov 2007Est. completion: Feb 2008103 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.